Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234910 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
A Phase 3 study of HIV Infection, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
- 1
- Study location
NCT00234910 is a Phase 3 study of HIV Infection that has completed, run by Abbott. The registered enrollment target is 152 participants, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00234910, a Phase 3 study of HIV Infection, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm.
Conditions Studied
Interventions
- DRUG Tenofovir DF
- DRUG lopinavir/ritonavir with 2 Nucleoside RTIs
Study Locations (1)
Illinois
- Global Medical Information-Abbott - Abbott Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234910
The ClinicalTrials.gov registry entry for NCT00234910 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (37% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which Tenofovir DF is the first listed.
NCT00234910 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00234910 about?
NCT00234910 is a clinical study titled "Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients". The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm.
What is the current status of trial NCT00234910?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2005-01. Estimated completion is 2008-06.
What conditions does trial NCT00234910 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT00234910?
The interventions under investigation include: Tenofovir DF (DRUG), lopinavir/ritonavir with 2 Nucleoside RTIs (DRUG).
Who is sponsoring clinical trial NCT00234910?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00234910 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
ACTIVE NOT RECRUITING · Phase 3
-
Comparative Study of Three NNRTI-Sparing HAART Regimens
COMPLETED · Phase 3
-
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
COMPLETED · Phase 3
-
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
COMPLETED · Phase 3
-
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
COMPLETED · Phase 3
-
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.